Core Viewpoint - Novo Nordisk A/S has announced plans to acquire Akero Therapeutics for approximately $4.7 billion, aiming to enhance its position in the weight loss and obesity market, particularly in treating metabolic dysfunction-associated steatohepatitis (MASH) [1][2][3] Group 1: Acquisition and Strategic Moves - The acquisition of Akero Therapeutics is set to close in early 2026 and is part of Novo Nordisk's strategy to compete with Eli Lilly in the obesity treatment market [1][2] - Akero's drug candidate, efruxifermin (EFX), is in Phase 3 trials and could become a leading treatment for MASH, which is linked to obesity [2][3] - Analysts estimate the MASH market could be valued between $20 billion and $40 billion once effective therapies are available [3] Group 2: Market Position and Growth Potential - Novo Nordisk's Wegovy was the first GLP-1 drug approved for MASH treatment, indicating the company's success in a competitive landscape [4] - The market for GLP-1 drugs is projected to grow to $150 billion by 2034, a tenfold increase from $15 billion in 2024 [6] - The company plans to launch an oral version of Wegovy in early 2026, which may broaden access to treatments [7][8] Group 3: Stock Performance and Analyst Insights - The current stock price of Novo Nordisk is $56.84, with a consensus price target of $76, suggesting a potential upside of approximately 34% [9][10] - Analysts forecast earnings growth of around 21%, indicating that the stock may be undervalued compared to the broader market [10] - Institutional buying has outpaced selling in recent quarters, although institutional ownership remains low [11]